NASDAQ:CSTL Castle Biosciences (CSTL) Stock Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free CSTL Stock Alerts $18.75 -0.20 (-1.06%) (As of 09:44 AM ET) Add Compare Share Share Today's Range$18.53▼$18.9650-Day Range$18.06▼$25.3052-Week Range$9.26▼$26.70Volume23,063 shsAverage Volume257,630 shsMarket Capitalization$514.69 millionP/E RatioN/ADividend YieldN/APrice Target$31.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Castle Biosciences alerts: Email Address Castle Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside63.6% Upside$31.00 Price TargetShort InterestHealthy4.41% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.87Based on 9 Articles This WeekInsider TradingSelling Shares$1.47 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.01) to ($1.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.95 out of 5 starsMedical Sector423rd out of 946 stocksMedical Laboratories Industry12th out of 20 stocks 3.5 Analyst's Opinion Consensus RatingCastle Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $31.00, Castle Biosciences has a forecasted upside of 63.6% from its current price of $18.95.Amount of Analyst CoverageCastle Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.41% of the outstanding shares of Castle Biosciences have been sold short.Short Interest Ratio / Days to CoverCastle Biosciences has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Castle Biosciences has recently decreased by 3.20%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCastle Biosciences does not currently pay a dividend.Dividend GrowthCastle Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CSTL. Previous Next 3.3 News and Social Media Coverage News SentimentCastle Biosciences has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Castle Biosciences this week, compared to 3 articles on an average week.Search Interest10 people have searched for CSTL on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Castle Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Castle Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,465,354.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Castle Biosciences is held by insiders.Percentage Held by Institutions85.75% of the stock of Castle Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Castle Biosciences are expected to grow in the coming year, from ($3.01) to ($1.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Castle Biosciences is -8.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Castle Biosciences is -8.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCastle Biosciences has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaLike Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. Click here and see how to get a copy. About Castle Biosciences Stock (NASDAQ:CSTL)Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Read More CSTL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CSTL Stock News HeadlinesMarch 16, 2024 | insidertrades.comDerek J. Maetzold Sells 4,131 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockMarch 12, 2024 | insidertrades.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $49,266.44 in StockMarch 19, 2024 | Porter & Company (Ad)Urgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.March 19, 2024 | businesswire.comLeading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation TherapyMarch 16, 2024 | finance.yahoo.comCSTL Apr 2024 17.500 callMarch 15, 2024 | finance.yahoo.comNew Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and OlderMarch 15, 2024 | businesswire.comNew Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences' IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and OlderMarch 13, 2024 | seekingalpha.comBio-Techne and Qiagen had the biggest increase in short interest levels last month - BairdMarch 19, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…March 12, 2024 | morningstar.comCastle Biosciences Inc CSTLMarch 12, 2024 | businesswire.comCastle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor ForumMarch 12, 2024 | americanbankingnews.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 2,372 Shares of StockMarch 8, 2024 | businesswire.comCastle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual MeetingMarch 7, 2024 | businesswire.comIn Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk SubgroupsMarch 2, 2024 | finance.yahoo.comCastle Biosciences, Inc. (NASDAQ:CSTL) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesMarch 1, 2024 | seekingalpha.comCastle Biosciences, Inc. (CSTL) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | markets.businessinsider.comOutperform Rating for Castle Biosciences Amid Strong Market Presence and Growth ProspectsMarch 1, 2024 | finance.yahoo.comCastle Biosciences, Inc. (NASDAQ:CSTL): Are Analysts Optimistic?March 1, 2024 | finance.yahoo.comCastle Biosciences Full Year 2023 Earnings: Beats ExpectationsFebruary 29, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Immunocore Holdings (IMCR), Voyager Therapeutics (VYGR) and Castle Biosciences (CSTL)February 29, 2024 | finance.yahoo.comQ4 2023 Castle Biosciences Inc Earnings CallFebruary 29, 2024 | finance.yahoo.comCastle Biosciences, Inc. (NASDAQ:CSTL) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | investing.comCastle Biosciences Inc (CSTL)February 28, 2024 | benzinga.comRecap: Castle Biosciences Q4 EarningsFebruary 28, 2024 | msn.comCastle Biosciences files for $300M mixed securities shelfFebruary 28, 2024 | finance.yahoo.comCastle Biosciences Inc (CSTL) Reports Robust Revenue Growth and Improved Margins in 2023February 28, 2024 | finance.yahoo.comCastle Biosciences Reports Fourth Quarter and Full-Year 2023 ResultsSee More Headlines Receive CSTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2021Today3/19/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:CSTL CUSIPN/A CIK1447362 Webcastlebiosciences.com Phone(866) 788-9007FaxN/AEmployees587Year FoundedN/APrice Target and Rating Average Stock Price Target$31.00 High Stock Price Target$37.00 Low Stock Price Target$25.00 Potential Upside/Downside+63.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,470,000.00 Net Margins-26.15% Pretax Margin-26.10% Return on Equity-14.92% Return on Assets-13.20% Debt Debt-to-Equity RatioN/A Current Ratio6.20 Quick Ratio6.04 Sales & Book Value Annual Sales$219.79 million Price / Sales2.37 Cash FlowN/A Price / Cash FlowN/A Book Value$14.54 per share Price / Book1.30Miscellaneous Outstanding Shares27,450,000Free Float25,336,000Market Cap$520.04 million OptionableOptionable Beta0.90 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Derek J. Maetzold (Age 62)Founder, CEO, President & Director Comp: $1.45MMr. Frank Stokes (Age 54)CFO & Treasurer Comp: $849.36kMs. Kristen M. Oelschlager R.N. (Age 56)Chief Operating Officer Comp: $782.7kMr. Tobin W. Juvenal (Age 64)Chief Commercial Officer Comp: $782.7kCamilla ZuckeroVice President of Investor Relations & Corporate AffairsMs. Alice Bahner IzzoSenior Vice President of MarketingMr. Kevin DomanVice President of SalesMs. Keli GreenbergVP of Human Resources & Executive Director of Human ResourcesDr. Robert W. Cook Ph.D. (Age 52)Senior Vice President of Research & Development Dr. Matthew Goldberg M.D.Senior Vice President of MedicalMore ExecutivesKey CompetitorsCareDxNASDAQ:CDNACelcuityNASDAQ:CELCFulgent GeneticsNASDAQ:FLGTSera PrognosticsNASDAQ:SERAHH&L AcquisitionNYSE:HHLAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 22,093 shares on 3/11/2024Ownership: 5.324%Derek J MaetzoldSold 2,372 sharesTotal: $49,266.44 ($20.77/share)Derek J MaetzoldSold 4,131 sharesTotal: $88,444.71 ($21.41/share)Daniel BradburySold 23,323 sharesTotal: $482,319.64 ($20.68/share)Goldman Sachs Group Inc.Sold 71,362 shares on 3/1/2024Ownership: 0.299%View All Insider TransactionsView All Institutional Transactions CSTL Stock Analysis - Frequently Asked Questions Should I buy or sell Castle Biosciences stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CSTL shares. View CSTL analyst ratings or view top-rated stocks. What is Castle Biosciences' stock price target for 2024? 3 brokerages have issued 1-year price targets for Castle Biosciences' stock. Their CSTL share price targets range from $25.00 to $37.00. On average, they expect the company's stock price to reach $31.00 in the next twelve months. This suggests a possible upside of 63.6% from the stock's current price. View analysts price targets for CSTL or view top-rated stocks among Wall Street analysts. How have CSTL shares performed in 2024? Castle Biosciences' stock was trading at $21.58 on January 1st, 2024. Since then, CSTL stock has decreased by 12.2% and is now trading at $18.9450. View the best growth stocks for 2024 here. When is Castle Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our CSTL earnings forecast. How were Castle Biosciences' earnings last quarter? Castle Biosciences, Inc. (NASDAQ:CSTL) issued its quarterly earnings data on Sunday, November, 7th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.13. The business had revenue of $23.48 million for the quarter, compared to analyst estimates of $23.66 million. Castle Biosciences had a negative trailing twelve-month return on equity of 14.92% and a negative net margin of 26.15%. During the same quarter in the previous year, the business posted ($0.23) EPS. What ETF holds Castle Biosciences' stock? First Trust Nasdaq Lux Digital Health Solutions ETF holds 98 shares of CSTL stock, representing 0.21% of its portfolio. What guidance has Castle Biosciences issued on next quarter's earnings? Castle Biosciences issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $235.0 million-$240.0 million, compared to the consensus revenue estimate of $214.7 million. What other stocks do shareholders of Castle Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC). When did Castle Biosciences IPO? (CSTL) raised $50 million in an IPO on Thursday, July 25th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. SVB Leerink and Baird acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. Who are Castle Biosciences' major shareholders? Castle Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (9.63%), Granahan Investment Management LLC (8.05%), Principal Financial Group Inc. (5.89%), Vanguard Group Inc. (5.43%), Vanguard Group Inc. (5.32%) and Bellevue Group AG (4.58%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Ellen Goldberg, Frank Stokes, Jeffrey E Eberwein, Kristen M Oelschlager, Tiffany Olson and Tobin W Juvenal. View institutional ownership trends. How do I buy shares of Castle Biosciences? Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CSTL) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaBiden out June 13?Paradigm PressMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyBuy this small stock before coming AI Tidal WaveChaikin AnalyticsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.